- FILTERS Advanced
- Product Type
- Clonality
- Application
- Species / Reactivity
- Source / Host
- CE / IVD
- Clone ID
- Supplier
- EXCLUDE FILTERS
- Clonality
- Application
- Species / Reactivity
- Clone ID
- Supplier
| Name | Art no | Species Reactivity | Application | Conjugation | Clone | Size | Price |
|---|---|---|---|---|---|---|---|
|
Ab00126-35.0
|
human, monkey
|
FC
|
|
10F381 (rituximab)
|
200 µg
|
||
|
Ab00126-26.0
|
human, monkey
|
FC
|
|
10F381 (rituximab)
|
200 µg
|
||
|
Ab00126-26.0-BT
|
human, monkey
|
FC
|
|
10F381 (rituximab)
|
1 mg
|
||
|
Ab00126-35.0-BT
|
human, monkey
|
FC
|
|
10F381 (rituximab)
|
1 mg
|
||
|
Ab00728-36.0-BT
|
human, monkey
|
Block, IP, FC
|
|
hL22 (Epratuzumab)
|
1 mg
|
||
|
Ab00728-36.0
|
human, monkey
|
Block, IP, FC
|
|
hL22 (Epratuzumab)
|
200 µg
|
||
|
Ab00728-35.0
|
human, monkey
|
Block, IP, FC
|
|
hL22 (Epratuzumab)
|
200 µg
|
||
|
Ab00728-37.0-BT
|
human, monkey
|
Block, IP, FC
|
|
hL22 (Epratuzumab)
|
1 mg
|
||
|
Ab00728-37.0
|
human, monkey
|
Block, IP, FC
|
|
hL22 (Epratuzumab)
|
200 µg
|
||
|
Ab00728-26.0
|
human, monkey
|
Block, IP, FC
|
|
hL22 (Epratuzumab)
|
200 µg
|
||
|
Ab00728-26.0-BT
|
human, monkey
|
Block, IP, FC
|
|
hL22 (Epratuzumab)
|
1 mg
|
||
|
Ab00728-35.0-BT
|
human, monkey
|
Block, IP, FC
|
|
hL22 (Epratuzumab)
|
1 mg
|
||
|
Ab00170-26.0-BT
|
human
|
IF, IHC, WB
|
|
YTH 12.5
|
1 mg
|
||
|
Ab00170-26.0
|
human
|
IF, IHC, WB
|
|
YTH 12.5
|
200 µg
|
||
|
Ab00217-35.0
|
human, monkey
|
WB, IP, IF, IHC, FC
|
|
MT310
|
200 µg
|
||
|
Ab00217-26.0-BT
|
human, monkey
|
WB, IP, IF, IHC, FC
|
|
MT310
|
1 mg
|
||
|
Ab00217-37.0-BT
|
human, monkey
|
WB, IP, IF, IHC, FC
|
|
MT310
|
1 mg
|
||
|
Ab00217-26.0
|
human, monkey
|
WB, IP, IF, IHC, FC
|
|
MT310
|
200 µg
|
||
|
Ab00217-35.0-BT
|
human, monkey
|
WB, IP, IF, IHC, FC
|
|
MT310
|
1 mg
|
||
|
Ab00217-36.0-BT
|
human, monkey
|
WB, IP, IF, IHC, FC
|
|
MT310
|
1 mg
|
||
|
Ab00217-36.0
|
human, monkey
|
WB, IP, IF, IHC, FC
|
|
MT310
|
200 µg
|
||
|
Ab00217-37.0
|
human, monkey
|
WB, IP, IF, IHC, FC
|
|
MT310
|
200 µg
|
||
|
Ab00129-26.0
|
human
|
FC, IP, IHC, Activation
|
|
G28.5
|
200 µg
|
||
|
Ab00129-36.0
|
human
|
FC, IP, IHC, Activation
|
|
G28.5
|
200 µg
|
||
|
Ab00129-26.0-BT
|
human
|
FC, IP, IHC, Activation
|
|
G28.5
|
1 mg
|
||
|
Ab00129-35.0-BT
|
human
|
FC, IP, IHC, Activation
|
|
G28.5
|
1 mg
|
||
|
Ab00129-36.0-BT
|
human
|
FC, IP, IHC, Activation
|
|
G28.5
|
1 mg
|
||
|
Ab00129-35.0
|
human
|
FC, IP, IHC, Activation
|
|
G28.5
|
200 µg
|
||
|
Ab00129-37.0
|
human
|
FC, IP, IHC, Activation
|
|
G28.5
|
200 µg
|
||
|
Ab00129-37.0-BT
|
human
|
FC, IP, IHC, Activation
|
|
G28.5
|
1 mg
|
||
|
Ab00124-35.0
|
human, monkey
|
FA, ELISA, IHC, FC, WB
|
|
Campath-1H
|
200 µg
|
||
|
Ab00124-26.0
|
human, monkey
|
FA, ELISA, IHC, FC, WB
|
|
Campath-1H
|
200 µg
|
||
|
Ab00124-35.0-BT
|
human, monkey
|
FA, ELISA, IHC, FC, WB
|
|
Campath-1H
|
1 mg
|
||
|
Ab00124-26.0-BT
|
human, monkey
|
FA, ELISA, IHC, FC, WB
|
|
Campath-1H
|
1 mg
|
||
|
Ab01039-26.0-BT
|
human, monkey
|
FC
|
|
YTC 182.20
|
1 mg
|
||
|
Ab01039-35.0-BT
|
human, monkey
|
FC
|
|
YTC 182.20
|
1 mg
|
||
|
Ab01038-35.0-BT
|
human, monkey
|
FC, IHC
|
|
YTC 141.1HL
|
1 mg
|
||
|
303-C3C001-F
|
|
|
|
|
1 ml
|
||
|
Ab00102-36.0-BT
|
|
|
|
4-4-20 (enhanced)
|
1 mg
|
||
|
Ab00102-35.0
|
|
|
|
4-4-20 (enhanced)
|
200 µg
|
||
|
Ab00102-36.0
|
|
|
|
4-4-20 (enhanced)
|
200 µg
|
||
|
Ab00102-35.0-BT
|
|
|
|
4-4-20 (enhanced)
|
1 mg
|
||
|
Ab00102-26.0
|
|
|
|
4-4-20 (enhanced)
|
200 µg
|
||
|
Ab00102-26.0-BT
|
|
|
|
4-4-20 (enhanced)
|
1 mg
|
||
|
Ab00102-37.0-BT
|
|
|
|
4-4-20 (enhanced)
|
1 mg
|
||
|
Ab00102-37.0
|
|
|
|
4-4-20 (enhanced)
|
200 µg
|
||
|
Ab01102-35.0-BT
|
virus
|
ELISA, Neutralization, WB
|
|
37.7H
|
1 mg
|
||
|
Ab01102-26.0
|
virus
|
ELISA, Neutralization, WB
|
|
37.7H
|
200 µg
|
||
|
Ab01102-26.0-BT
|
virus
|
ELISA, Neutralization, WB
|
|
37.7H
|
1 mg
|
||
|
Ab01102-35.0
|
virus
|
ELISA, Neutralization, WB
|
|
37.7H
|
200 µg
|
